Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

BOULDER -- Inscripta , a gene-editing technology company, today announced MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in... Read More

Thursday December 20, 2018 0 comments Tags: Boulder, Inscripta, MAD7, Kevin Ness

Inscripta hires Jason Gammack as first chief commercial officer

Inscripta hires Jason Gammack as first chief commercial officer

BOULDER -- Gene-editing technology company Inscripta today announced the hiring of Jason T. Gammac kas the company's first chief commercial officer. Gammack, a 25-year veteran of life... Read More

Friday November 2, 2018 0 comments Tags: Boulder, Inscripta, Jason Gammack, Kevin Ness